Discrepancies between direct molecular surveillance and culture-based surveillance for carbapenemase-producing Enterobacterales (CPE) complicate infection control decision-making. This study investigated co-colonization patterns of multidrug-resistant organisms (MDROs) in patients with discordant results. From March to December 2023, two rectal swabs were simultaneously collected from high-risk patients at a tertiary hospital: one for direct Xpert Carba-R assay and one for culture-based molecular assay. Among 4,120 screened patients, 142 (3.4%) tested positive by direct molecular assay, of whom 49 (34.5%) showed discordant results. Discordance included culture-negative patients (n=38) and patients with different carbapenemase genes detected between methods (n=11). Among 38 culture-negative patients, 14 (36.8%) harbored MDROs from clinical specimens: multidrug-resistant Pseudomonas aeruginosa (MRPA) (n=9, 23.7%), multidrug-resistant Acinetobacter baumannii (n=2, 5.3%), CPE (n=2, 5.3%), and vancomycin-resistant enterococci (n=1, 2.6%). For gene-level analysis, each unconfirmed carbapenemase gene was analyzed separately, yielding 51 discordant detections from 49 patients. Discordant bla NDM detection (n=27) was associated with MRPA isolation compared to other carbapenemase genes (11/27, 40.7%, P=0.018), predominantly from respiratory and urinary specimens. Median time from surveillance to MDRO detection was 2 days (IQR 0.5–6.5). Positive direct molecular CPE results indicate a broader MDRO burden, supporting consideration of comprehensive infection control measures even when culture results are negative.
Jun et al. (Sun,) studied this question.